Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan
Ehsan Shabbir(Wright State University), Guido Tricot, Lindsay Dozeman(University of Iowa Hospitals and Clinics), Yogesh Jethava(University of Iowa), Sarah L. Mott(University of Iowa), Umar Farooq(Wake Forest University)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
|New England Journal of Medicine|2023|437